Xortx reports that independent proxy firm, iss, recommends shareholders vote for the share consolidation resolution

Calgary, alberta, oct. 12, 2023 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that institutional shareholder services inc. (“iss”) has recommended that the company's shareholders vote for the proposed share consolidation resolution at xortx's special meeting of shareholders scheduled to be held at 3710 – 33rd avenue nw, calgary, alberta, canada t2l 2m1 at 10:00 a.m. (calgary time), on wednesday, october 25, 2023.
XRTX Ratings Summary
XRTX Quant Ranking